Author: Steve
-
Most Cancer Patients Will Be Treated in Integrated Delivery Networks (IDN) and Cancer Institutions by 2016, Predicts New Report
By 2016, Inside Oncology’s new market intelligence report: Academic Cancer Centers (NCCC): Trends Impacting Key Account Management is predicting that
-
Generex announces presentations of Antigen express AE37 Breast Cancer vaccine data at ASCO 2012
WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ — Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts
-
Sorry Rush Limbaugh – Avastin® Reimbursement is “Controlled” by the Compendia NOT the FDA or Medicare!
For those of you who have been following this blog you will recall that I have spent a lot of time discussing cancer drug costs and the lack of
-
Will Medicare Cover Provenge? A Dendreon “Hockey Stick” Event Approaches
While winter is approaching and the hockey season has already begun for sports fans, another kind of hockey related event is approaching
-
Beyond the Tipping Point: Medicare Will Control the Rising Cost of Cancer Drugs
The question is no longer whether or not Medicare will do it but when and how. The initiation of a National Coverage Decision
-
Does Folotyn® work in NSCLC? Allos Therapeutics Reports Phase 2 Results
On Wednesday the 28th Allos announced the results of their randomized phase 2 study comparing Folotyn
-
Buying Opportunities? Dendreon; Antisoma
On July 1st CMS announced that Dendreon’s Provenge® will undergo a National Coverage Determination (NCD).
-
Catch a rising star.
This past ASCO in Chicago was something like the 18th or 19th one that I have attended, and it has grown from a few thousand physicians to